Treatment of Diabetic Neuropathy with A Novel PAR1-Targeting Molecule.
PAR1
diabetes mellitus
peripheral neuropathy
streptozotocin
thrombin
Journal
Biomolecules
ISSN: 2218-273X
Titre abrégé: Biomolecules
Pays: Switzerland
ID NLM: 101596414
Informations de publication
Date de publication:
13 11 2020
13 11 2020
Historique:
received:
07
10
2020
revised:
04
11
2020
accepted:
10
11
2020
entrez:
18
11
2020
pubmed:
19
11
2020
medline:
7
9
2021
Statut:
epublish
Résumé
Diabetic peripheral neuropathy (DPN) is a disabling common complication of diabetes mellitus (DM). Thrombin, a coagulation factor, is increased in DM and affects nerve function via its G-protein coupled protease activated receptor 1 (PAR1). A novel PAR1 modulator (PARIN5) was designed based on the thrombin PAR1 recognition site. Coagulation, motor and sensory function and small fiber loss were evaluated by employing the murine streptozotocin diabetes model. PARIN5 showed a safe coagulation profile and showed no significant effect on weight or glucose levels. Diabetic mice spent shorter time on the rotarod ( PARIN5 is a novel pharmacological approach for prevention of DPN development, via PAR1 pathway modulation.
Identifiants
pubmed: 33203057
pii: biom10111552
doi: 10.3390/biom10111552
pmc: PMC7698286
pii:
doi:
Substances chimiques
Blood Glucose
0
Peptide Fragments
0
Receptor, PAR-1
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Israeli Ministry of Economy and Industry
ID : 57655
Déclaration de conflit d'intérêts
J.C. and E.S.S. hold the patent for the PARIN5 molecule. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
Références
Neural Regen Res. 2019 Dec;14(12):2043-2053
pubmed: 31397331
Neurology. 1997 Mar;48(3):708-11
pubmed: 9065552
Hippocampus. 2014 Aug;24(8):1030-8
pubmed: 24753100
Neurology. 2003 Jan 14;60(1):108-11
pubmed: 12525727
PLoS One. 2019 Jul 5;14(7):e0219453
pubmed: 31276565
Neurotherapeutics. 2009 Oct;6(4):638-47
pubmed: 19789069
Pediatr Neurol. 2018 Mar;80:51-60
pubmed: 29429781
Arch Neurol. 2004 Oct;61(10):1613-5
pubmed: 15477521
Front Neurol. 2018 Dec 17;9:1087
pubmed: 30619047
Ann Neurol. 2014 Feb;75(2):303-8
pubmed: 24740641
J Neurosci. 2013 Apr 3;33(14):6181-90
pubmed: 23554499
Neurology. 2006 Sep 12;67(5):786-91
pubmed: 16966538
Eur J Neurol. 2010 Jul;17(7):903-12, e44-9
pubmed: 20642627
World J Clin Oncol. 2017 Aug 10;8(4):329-335
pubmed: 28848699
Mol Cell Neurosci. 2017 Mar;79:23-33
pubmed: 28064059
J Diabetes Complications. 2001 Jan-Feb;15(1):44-54
pubmed: 11259926
J Am Coll Cardiol. 1996 Mar 1;27(3):560-6
pubmed: 8606265
Eur J Histochem. 2020 Mar 30;64(2):
pubmed: 32236088
Bull Exp Biol Med. 2004 Nov;138(5):463-6
pubmed: 15723127
Nat Rev Endocrinol. 2011 Nov 08;8(4):228-36
pubmed: 22064493
Curr Opin Neurol. 1999 Oct;12(5):553-63
pubmed: 10590892
CNS Neurosci Ther. 2010 Oct;16(5):e157-68
pubmed: 20626434
J Peripher Nerv Syst. 2017 Sep;22(3):182-190
pubmed: 28573768
Nat Clin Pract Neurol. 2007 Jun;3(6):331-40
pubmed: 17549059
J Neurobiol. 1996 Jun;30(2):255-66
pubmed: 8738754
Clin Exp Immunol. 2008 Nov;154(2):235-46
pubmed: 18778365
Brain. 2008 Apr;131(Pt 4):1113-22
pubmed: 18299297
Mol Med. 2000 May;6(5):410-29
pubmed: 10952021
Lancet. 2005 Nov 5;366(9497):1653-66
pubmed: 16271648
Front Neurol. 2019 Jan 04;9:1139
pubmed: 30662428